High-Value Candidates in GI Diseases
Our lead candidate, TP-252, is rapidly advancing through pre-clinical evaluations, including biological profiling, drug product manufacturing and safety studies, to begin clinical studies in 2018 for treatment of ulcerative colitis (UC). We are also pursuing TP-252 for familial adenomatous polyposis (FAP), a rare genetic disease.
Beyond TP-252, we are investigating a new drug class known as Specialized Proresolving Mediators (SPMs) that act on the immune system to resolve inflammation. We are developing TP-317, a novel SPM-based derivative using our HEALER technology, for an orphan indication in inflammatory bowel disease (IBD).
|TP-252||EPA-FFA||Ulcerative Colitis||Phase I to Begin in 2018|
|Pediatric FAP||Pre-IND Stage|
|TP-317||SPM||Orphan IBD||Exploratory Studies|